Background Recent evidence supports the use of machine perfusion technologies (MP) for marginal liver grafts. Their effect on enhanced recovery, however, remains uncertain. Objectives To identify areas in which MP might contribute to an ERAS program and to provide expert panel recommendations. Data sources Ovid MEDLINE, Embase, Scopus, Google Scholar, and Cochrane Central. Methods Systematic review and meta‐analysis following PRISMA guidelines and recommendations using the GRADE approach. CRD42021237713 Results Both hypothermic (HMP) and normothermic (NMP) machine perfusion demonstrated significant benefits in preventing postreperfusion syndrome (PRS) (HMP OR .33, .15‐.75 CI; NMP OR .51, .29‐.90 CI) and early allograft dysfunction (EAD) (HMP OR .51, .35‐.75 CI; NMP OR .66, .45‐.97 CI), while shortening LOS (HMP MD ‐3.9; NMP MD ‐12.41). Only NMP showed a significant decrease in the length of ICU stay (L‐ICU) (MD ‐7.07, ‐8.76; ‐5.38 CI), while only HMP diminishes the likelihood of major complications. Normothermic regional perfusion (NRP) reduces EAD (OR .52, .38–.70 CI) and primary nonfunction (PNF) (OR .51, .27‐.98 CI) without effect on L‐ICU and LOS. Conclusions The use of HMP decreases PRS and EAD, specifically for marginal grafts. This is supported by a shorter LOS and a lower rate of major postoperative complications (QOE; moderate | Recommendation; Strong). NMP reduces the incidence of PRS and EAD with associated shortening in L‐ICU for both DBD and DCD grafts (QOE; moderate | Recommendation; High) This technology also shortens the length of hospital stay (QOE; low | Recommendation; Strong). NRP decreases the likelihood of EAD (QOE; moderate) and the risk of PNF (QOE; low) when compared to both DBD and SRR‐DCD grafts preserved in SCS. (Recommendation; Strong).